iShares Biotechnology ETF
522 hedge funds and large institutions have $4.15B invested in iShares Biotechnology ETF in 2016 Q4 according to their latest regulatory filings, with 127 funds opening new positions, 172 increasing their positions, 148 reducing their positions, and 60 closing their positions.
161.41% more ownership
Funds ownership: 0% → 161.41% (+161%)
112% more first-time investments, than exits
New positions opened: 127 | Existing positions closed: 60
16% more repeat investments, than reductions
Existing positions increased: 172 | Existing positions reduced: 148
13% more funds holding
Funds holding: 463 → 522 (+59)
10% less capital invested
Capital invested by funds: $4.63B → $4.15B (-$479M)
16% less funds holding in top 10
Funds holding in top 10: 25 → 21 (-4)
35% less call options, than puts
Call options by funds: $641M | Put options by funds: $990M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$46.6M |
| 2 |
Morgan Stanley
New York
|
+$46.4M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$45.1M |
| 4 |
N
Natixis
Paris,
France
|
+$41.1M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$34.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$254M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$173M |
| 3 |
Goldman Sachs
New York
|
-$165M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$79.3M |
| 5 |
SG Americas Securities
New York
|
-$56.1M |
IBB Hedge Fund Activity: Q4 2016 in Review
522 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q4 2016, worth a combined $4.15B — down 10% from $4.63B a quarter earlier.
Buyers outnumbered sellers: 127 funds opened new IBB positions and 60 closed out — a net gain of 67 holders — while 172 added to existing stakes and 148 trimmed.
The largest buyer was Jane Street, adding an estimated $46.6M. The largest seller was Citigroup, cutting an estimated $254M.
- 522 institutional investors held iShares Biotechnology ETF (IBB) as of Q4 2016, up from 463 in Q3 2016.
- Funds reported $4.15B of iShares Biotechnology ETF stock for Q4 2016, down 10% quarter-over-quarter.
- 127 funds opened new iShares Biotechnology ETF positions in Q4 2016 and 60 closed out, a net change of +67 holders.
- The largest iShares Biotechnology ETF buyer in Q4 2016 was Jane Street, an estimated $46.6M added.
- The largest iShares Biotechnology ETF seller in Q4 2016 was Citigroup, an estimated $254M sold.
Based on aggregated 13F filings for Q4 2016.